# FDA Approves Lipfendra (Enlicitide), First Oral PCSK9 Inhibitor Pill, for Hypercholesterolemia

> fda · REPORTED · 2026-07-17

The FDA approved Merck's Lipfendra (enlicitide), marking a landmark as the first oral PCSK9 inhibitor pill approved for hypercholesterolemia including heterozygous familial hypercholesterolemia. The oral formulation addresses a major patient adherence gap compared to injectable PCSK9 inhibitors currently on the market.

About Merck & Co.: Merck & Co. is a global pharmaceutical company that develops and commercializes prescription medicines, vaccines, and biological therapies across a broad range of disease areas including cardiovascular disease.

- Company: Merck & Co.
- Sector: cardiology
- Primary source: https://tldrbio.tech/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.